Microbiological identification and in vitro sensitivity of Candida isolates from the oral cavity of HIV-positive individuals;Identificação microbiológica e sensibilidade in vitro de Candida isoladas da cavidade oral de indivíduos HIV positivos

Revista da Sociedade Brasileira de Medicina Tropical

Volumn 40, Issue 3, 2007, Pages 272-276

  Wingeter, Márcia Arias ^a   Guilhermetti, Eliana ^b   Shinobu, Cristiane Suemi ^b   Takaki, Ione ^b   Svidzinski, Terezinha Inez Estivalet ^b,c  

^a Hospital Universitário Regional de Maringá   (Brazil)

^b STATE UNIVERSITY OF MARINGÁ   (Brazil)

^c NONE   (Brazil)

Author keywords

Antifungal agents; Candida albicans; HIV positive patients; Oral candidiasis

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; ANTIFUNGAL AGENT; CETOCONAZOL; FLUCONAZOLE; FUNGIZON; ITRACONAZOLE; NYSTATIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CELL VIABILITY; CLINICAL PRACTICE; CONCENTRATION RESPONSE; CONTROLLED STUDY; FUNGUS ISOLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; MICROBIOLOGICAL EXAMINATION; NONHUMAN; THRUSH;

CANDIDA; CANDIDA ALBICANS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 34547205087     PISSN: 00378682     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0037-86822007000300004     Document Type: Article

References (26)

1. Bachmann SP, Patterson TF, Ribot JLL. In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. Journal Clinical Microbiology 40:2228-2230, 2002.
2. Campisi G, Pizzo G, Milici ME, Mancuso S, Margiotta V. Candidal carriage in the oral cavity of human immunodeficiency virus-infected subjects. Oral Medicine 93 :281-286, 2002.
3. Campos J, Del Romero J, Castilha J, Garcia S, Rodriguez C, Bascones A. Oral candidiasis as a clinical marker related to viral load, CD4 lymphocyte count and CD4 lynphocyte percentage in HIV-infected patients. Journal Oral Pathology Medicine 31:5-10, 2002.
4. Colombo AL, Matta D, Almeida LP, Rosas R. Fluconazole susceptibility of brazilian Candida isolates assessed by a disk diffusion method. The Brazilian Journal of Infectious Diseases 6:118-123, 2002.
5. Eyeson JD, Tenant-Flowers M, Cooper DJ, Johnson NW, Warnakulasuriya KAS. Oral manifestations of an HIV positive cohort in the era of highly active anti-retroviral therapy (HAART) in South London. Journal Oral Pathology Medicine 31:169-174, 2002.
6. Fidel Jr PL. Immunity to Candida. Oral Diseases 8:69-75, 2002.
7. Goldman M, Cloud GA, Smedema M, Lemonte A, Connolly P, Mckinsey D, Kauffman CA, Moskovitz B, Wheat J and members of the National Institute of Allergy and Infectious Diseases Mycoses Study Group. Does long-term itraconazole prophylaxis result in vitro azole resistance in mucosal Candida albicans isolates from persons which advanced human immunodeficiency virus infection? Antimicrobial Agents Chemotherapy 44:1585-1587, 2000.
8. Greenspan D, Gange SJ, Phelan JA, Navazesh M, Alves MEAF, MacPhail LA, Mulligan R, Greenspan JS. Incidence of oral lesions in HIV-1-infected women: Reduction a with HAART. Journal Dental Research 83:145-150, 2004.
9. Gupta E, Vajpayee M, Xess I, Seth P. Oral candidiasis in HIV-infected patients and its relation to CD4 + counts: an adjunct clinical marker of HIV disease progression. Tropical Doctor 36:127, 2006.
10. Kurtzman CP, Fell JW. The Yeast. A taxonomic study. Elsevier, Amsterdam, 1998.
11. Larone DH. Medically important fungi. A guide to identification. AMS Press, Washington, 1995.
12. Melo NR, Taguchi H, Jorge J, Pedro RJ, Almeida OP, Fukushima K, Nishimura K, Miyaji M. Oral Candida flora from Brazilian human immunodeficiency virus-infected patientes in the highly active antiretroviral therapy era. Memórias do Instituto Oswaldo Cruz 99:425-431, 2004.
13. Milan EP. Avaliação fenotípica e genotípica de leveduras isoladas da cavidade oral de pacientes com AIDS. Dissertaç ão de Doutorado, Universidade Federal de São Paulo, São Paulo, SP, 2001.
14. Ministério da Saúde. Secretaria de Vigilância em Saúde. Programa Nacional de DST e AIDS. Critérios de definição de casos de AIDS em adultos e crianças. Ministério da Saúde, Brasília, 2003.
15. Ministério da Saúde. Secretaria de Vigilância em Saúde. Programa Nacional de DST e AIDS. Boletim Epidemiológico AIDS - DST. Janeiro a Junho de 2004 1. Ministério da Saúde, Brasília, 2005.
16. National Committee for Laboratory Standards NCCLS. Reference method for broth dilution antifungal susceptibility testing of yeast. Approved Standard. NCCLS M27-A. 17:1-29, 1997.
17. Pádua RAF, Guilhermetti E, Svidzinski TIE. In vitro activity of antifungal agents on yeasts isolated from vaginal secretion. Acta Scientiarum. Health Sciences 25:51-54, 2003.
18. Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ, Diekema DJ. Caspofungin activity against clinical isolates of fluconazole-resistant Candida. Journal of Clinical Microbiology 41:5729-5731, 2003.
19. Powderly WG, Robinson K, Keath EJ. Molecular epidemiology of recurrent oral candidiasis in human immunodeficiency virus-positive patients: evidence for two patterns of recurrence. Journal of Infectious Diseases 168:463-466, 1993.
20. Rex JH, Rinald MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrobial Agents and Chemotherapy 39:1-8, 1995.
21. Rex JH, Walsh TJ, Sobel JD, Filler SG Pappas PG, Dismukes WE, Edwards JE. Pratice Guidelines for the Treatment of Candidiasis. Clinical Infectious Diseases 30:662-678, 2000.
22. Sánchez-Vargas LO, Ortiz-López NG, Villar M, Moragues MD, Aguirre JM, Cashat-Cruz M, Lopez-Ribot JL, Gaitán-Cepeda LA, Quindós G. Point prevalence, microbiology and susceptibility patterns of oral Candida isolates colonizing or infecting Mexican HIV/AIDS patients and healthy persons. Revista Iberoamamericana de Micología 22:83-92, 2005.
23. Sanglard D, Kuchler K, Ischer F, Pagani JL, Monod M. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrobial Agents Chemotherapy 39:2378-2386, 1995.
24. Sant'Ana PL, Milan EP, Martinez R, Telles FQ, Ferreira MS, Alcântara MTC, Carvalho MT, Colombo AL. Multicenter Brazilian study of oral Candida species isolated from AIDS patients. Memórias do Instituto Oswaldo Cruz 97:253-257, 2002.
25. Schechter M, Rachid M. Manual de HIV/AIDS. Revinter, Rio de Janeiro, 2004.
26. Telles FQ, Silva N, Carvalho MM, Alcântara AP, Matta D, Barberino MG, Bartezak S, Colombo AL. Evaluation of efficacy and safety of itraconazole oral solution for the treatment of oropharyngeal candidiasis in AIDS patients. The Brazilian Journal of Infectious Disease 5:60-66, 2002.